[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie's Imbruvica Approved for Type of Non-Hodgkin Lymphoma",
            "features": {
                "keywords": [
                    "Imbruvica",
                    "Non-Hodgkin Lymphoma",
                    "Approval"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's Imbruvica Approved for Type of Non-Hodgkin Lymphoma",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval",
            "features": {
                "keywords": [
                    "Rare Blood Cancer",
                    "FDA Approval",
                    "Drug Combo"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie's Rare Blood Cancer Drug Combo Snags FDA Approval",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "We Did The Math FTXH Can Go To $26",
            "features": {
                "keywords": [
                    "FTXH",
                    "Price Target",
                    "$26"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "We Did The Math FTXH Can Go To $26",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 5,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Benzinga Pro's 5 Stocks To Watch Today",
            "features": {
                "keywords": [
                    "Stocks To Watch",
                    "Today"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Benzinga Pro's 5 Stocks To Watch Today",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 3,
                "Impact": 3,
                "Duration": 2,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Today's Research Reports on Trending Tickers: AbbVie and Merck & Co.",
            "features": {
                "keywords": [
                    "Research Reports",
                    "Trending Tickers",
                    "AbbVie",
                    "Merck"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Today's Research Reports on Trending Tickers: AbbVie and Merck & Co.",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer",
            "features": {
                "keywords": [
                    "IMBRUVICA",
                    "Rituximab",
                    "FDA Approval",
                    "Chemotherapy-Free",
                    "Waldenström's Macroglobulinemia"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie Announces IMBRUVICA® (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 10
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?",
            "features": {
                "keywords": [
                    "ABBV",
                    "Earnings Report",
                    "Up 3.7%"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Up 3.7% Since Last Earnings Report: Can It Continue?",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]